{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:30:23Z","timestamp":1784748623033,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Genomic mutations drive the pathogenesis of myelodysplastic syndromes and acute myeloid leukemia. While morphological and clinical features have dominated the classical criteria for diagnosis and classification, incorporation of molecular data can illuminate functional pathobiology. Here we show that unsupervised machine learning can identify functional objective molecular clusters, irrespective of anamnestic clinico-morphological features, despite the complexity of the molecular alterations in myeloid neoplasia. Our approach reflects disease evolution, informed classification, prognostication, and molecular interactions. We apply machine learning methods on 3588 patients with myelodysplastic syndromes and secondary acute myeloid leukemia to identify 14 molecularly distinct clusters. Remarkably, our model shows clinical implications in terms of overall survival and response to treatment even after adjusting to the molecular international prognostic scoring system (IPSS-M). In addition, the model is validated on an external cohort of 412 patients. Our subclassification model is available via a web-based open-access resource (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/drmz.shinyapps.io\/mds_latent\">https:\/\/drmz.shinyapps.io\/mds_latent<\/jats:ext-link>).<\/jats:p>","DOI":"10.1038\/s41467-023-38515-4","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T16:02:00Z","timestamp":1685462520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Molecular patterns identify distinct subclasses of myeloid neoplasia"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4651-5125","authenticated-orcid":false,"given":"Tariq","family":"Kewan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arda","family":"Durmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waled","family":"Bahaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Terkawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1445-7947","authenticated-orcid":false,"given":"Hussein","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9614-6626","authenticated-orcid":false,"given":"Olisaemeka D.","family":"Ogbue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsha","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4274-8714","authenticated-orcid":false,"given":"Minako","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Ponvilawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayan","family":"Al-Share","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumika J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-3614","authenticated-orcid":false,"given":"Hetty E.","family":"Carraway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh K.","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Bat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9573-2690","authenticated-orcid":false,"given":"Yazan","family":"Madanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0196-2837","authenticated-orcid":false,"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-1509","authenticated-orcid":false,"given":"Valeria","family":"Visconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6837-4346","authenticated-orcid":false,"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"38515_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"},{"key":"38515_CR2","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2013-09-381665","volume":"122","author":"M Cazzola","year":"2013","unstructured":"Cazzola, M., Della Porta, M. G. & Malcovati, L. The genetic basis of myelodysplasia and its clinical relevance. Blood 122, 4021\u20134034 (2013).","journal-title":"Blood"},{"key":"38515_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1182\/hematology.2021000276","volume":"2021","author":"MT Voso","year":"2021","unstructured":"Voso, M. T. & Gurnari, C. Have we reached a molecular era in myelodysplastic syndromes. Hematol. Am. Soc. Hematol. Educ. Program 2021, 418\u2013427 (2021).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"38515_CR4","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola, M. Myelodysplastic syndromes. N. Engl. J. Med. 383, 1358\u20131374 (2020).","journal-title":"N. Engl. J. Med."},{"key":"38515_CR5","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg, P. L. et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454\u20132465 (2012).","journal-title":"Blood"},{"key":"38515_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.leukres.2018.06.012","volume":"71","author":"JM Bennett","year":"2018","unstructured":"Bennett, J. M. Morphologic dysplasia in Myelodysplastic Syndromes: How accurate are morphologists? Leuk. Res. 71, 34\u201335 (2018).","journal-title":"Leuk. Res."},{"key":"38515_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/leu.2014.161","volume":"29","author":"MG Della Porta","year":"2015","unstructured":"Della Porta, M. G. et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia 29, 66\u201375 (2015).","journal-title":"Leukemia"},{"key":"38515_CR8","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1182\/blood-2011-03-342642","volume":"118","author":"K Naqvi","year":"2011","unstructured":"Naqvi, K. et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118, 4690\u20134693 (2011).","journal-title":"Blood"},{"key":"38515_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1080\/10428194.2020.1861267","volume":"62","author":"X Chen","year":"2021","unstructured":"Chen, X. et al. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. Leuk. Lymphoma 62, 1226\u20131233 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"38515_CR10","unstructured":"Bernard Elsa, T. H. & Greenberg Peter L. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid 1, 1549\u20131556 (2022)."},{"key":"38515_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.20.01659","volume":"39","author":"M Bersanelli","year":"2021","unstructured":"Bersanelli, M. et al. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes. J, Clin. Oncol. 39, 1223\u20131233 (2021).","journal-title":"J, Clin. Oncol."},{"key":"38515_CR12","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg, P. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079\u20132088 (1997).","journal-title":"Blood"},{"key":"38515_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241\u2013247 (2014).","journal-title":"Leukemia"},{"key":"38515_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ng.3742","volume":"49","author":"H Makishima","year":"2017","unstructured":"Makishima, H. et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat. Genet. 49, 204\u2013212 (2017).","journal-title":"Nat. Genet."},{"key":"38515_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13001-y","volume":"10","author":"Y Nagata","year":"2019","unstructured":"Nagata, Y. et al. Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nat. Commun. 10, 5386 (2019).","journal-title":"Nat. Commun."},{"key":"38515_CR16","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.20.02810","volume":"39","author":"A Nazha","year":"2021","unstructured":"Nazha, A. et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J. Clin. Oncol. 39, 3737\u20133746 (2021).","journal-title":"J. Clin. Oncol."},{"key":"38515_CR17","doi-asserted-by":"publisher","unstructured":"Awada, H. et al. Personalized risk schemes and machine learning to empower genomic prognostication models in myelodysplastic syndromes. Int. J. Mol. Sci. 25, https:\/\/doi.org\/10.3390\/ijms23052802 (2022).","DOI":"10.3390\/ijms23052802"},{"key":"38515_CR18","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1182\/blood.2020005488","volume":"136","author":"Y Nagata","year":"2020","unstructured":"Nagata, Y. et al. Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. Blood 136, 2249\u20132262 (2020).","journal-title":"Blood"},{"key":"38515_CR19","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.1016\/S2352-3026(20)30121-6","volume":"7","author":"N Radakovich","year":"2020","unstructured":"Radakovich, N., Nagy, M. & Nazha, A. Machine learning in haematological malignancies. Lancet Haematol. 7, e541\u2013e550 (2020).","journal-title":"Lancet Haematol."},{"key":"38515_CR20","first-page":"1","volume":"61","author":"TBM Arthur White","year":"2014","unstructured":"Arthur White, T. B. M. BayesLCA: an R package for Bayesian latent class analysis. J. Stat. Softw. 61, 1\u201328 (2014).","journal-title":"J. Stat. Softw."},{"key":"38515_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson, B. D. et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108, 419\u2013425 (2006).","journal-title":"Blood"},{"key":"38515_CR22","doi-asserted-by":"publisher","first-page":"106639","DOI":"10.1016\/j.leukres.2021.106639","volume":"109","author":"A Radhachandran","year":"2021","unstructured":"Radhachandran, A. et al. A machine learning approach to predicting risk of myelodysplastic syndrome. Leuk. Res. 109, 106639 (2021).","journal-title":"Leuk. Res."},{"key":"38515_CR23","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1038\/s41375-018-0152-7","volume":"32","author":"Y Liang","year":"2018","unstructured":"Liang, Y. et al. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. Leukemia 32, 2659\u20132671 (2018).","journal-title":"Leukemia"},{"key":"38515_CR24","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1182\/bloodadvances.2019000192","volume":"3","author":"B Reilly","year":"2019","unstructured":"Reilly, B. et al. DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes. Blood Adv. 3, 2845\u20132858 (2019).","journal-title":"Blood Adv."},{"key":"38515_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64\u201369 (2011).","journal-title":"Nature"},{"key":"38515_CR26","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-21-0508","volume":"12","author":"EC Wheeler","year":"2022","unstructured":"Wheeler, E. C. et al. Integrative RNA-omics discovers GNAS alternative splicing as a phenotypic driver of splicing factor-mutant neoplasms. Cancer Discov. 12, 836\u2013855 (2022).","journal-title":"Cancer Discov."},{"key":"38515_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526\u2013531 (2018).","journal-title":"Nature"},{"key":"38515_CR28","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3324\/haematol.2017.166173","volume":"102","author":"M Meggendorfer","year":"2017","unstructured":"Meggendorfer, M., Haferlach, C., Kern, W. & Haferlach, T. Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes. Haematologica 102, 1502\u20131510 (2017).","journal-title":"Haematologica"},{"key":"38515_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/bjh.14269","volume":"175","author":"S Delic","year":"2016","unstructured":"Delic, S. et al. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Br. J. Haematol. 175, 419\u2013426 (2016).","journal-title":"Br. J. Haematol."},{"key":"38515_CR30","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood.2019004229","volume":"136","author":"L Palomo","year":"2020","unstructured":"Palomo, L. et al. Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms. Blood 136, 1851\u20131862 (2020).","journal-title":"Blood"},{"key":"38515_CR31","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41375-018-0150-9","volume":"32","author":"CM Hirsch","year":"2018","unstructured":"Hirsch, C. M. et al. Consequences of mutant TET2 on clonality and subclonal hierarchy. Leukemia 32, 1751\u20131761 (2018).","journal-title":"Leukemia"},{"key":"38515_CR32","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1109\/TPAMI.2020.3003660","volume":"43","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Deep autoencoding topic model with scalable hybrid Bayesian inference. IEEE Trans. Pattern Anal. Mach. Intell. 43, 4306\u20134322 (2021).","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."}],"updated-by":[{"DOI":"10.1038\/s41467-024-45644-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38515-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38515-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38515-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T08:03:29Z","timestamp":1707465809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38515-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38515"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-38515-4","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41467-024-45644-x","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"26 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-024-45644-x","URL":"https:\/\/doi.org\/10.1038\/s41467-024-45644-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.M. has received honoraria\/consulting fees from BluePrint Medicines, GERON, OncLive and MD Education; participated in advisory boards and received honoraria from Sierra Oncology, Stemline Therapeutics, Blueprint Medicines, Morphosys, Taiho Oncology, Rigel Pharmaceuticals and Novartis; and\u00a0received travel reimbursementfrom Blueprint Medicines, MD Education, and Morphosys. None of these relationships were related to this work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3136"}}